⁹⁰Yttrium (⁹⁰Y) ibritumomab tiuxetan (Zevalin®, BiogenIdec) radioimmunotherapy produces durable long-term responses and a long-term overall survival rate in heavily pre-treated patients with relapsed, refractory, or transformed B-cell non-Hodgkin?s lymphoma (NHL), according to a presentation given at the 46th Annual Meeting of the American Society of Hematology.
Go to Previous Page
Go to Next Page